NRD
MRSN

Nebula Research & Development’s Mersana Therapeutics MRSN Stock Holding History

Nebula Research & Development’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-628
Closed -$64.5K – 412
2023
Q1 		$64.5K Buy
+628
New +$88.1K 0.11% 217

Other funds holding MRSN

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Nebula Research & Development's MRSN Position: Q2 2023 in Review

Nebula Research & Development sold out of Mersana Therapeutics (MRSN) in Q2 2023, closing a stake of 628 shares — an estimated $64.5K sold.

Nebula Research & Development first reported a position in MRSN in Q1 2023 and held it in 1 quarter. The position peaked at $64.5K in Q1 2023. 147 funds tracked by Wall St. Rank hold MRSN as of Q2 2023.

  • Nebula Research & Development reported no remaining Mersana Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Nebula Research & Development sold 628 Mersana Therapeutics shares in Q2 2023, an estimated $64.5K.
  • Nebula Research & Development first reported a position in Mersana Therapeutics in Q1 2023 and held it in 1 quarter.
  • Nebula Research & Development's Mersana Therapeutics position peaked at $64.5K in Q1 2023.
  • 147 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2023.

Based on Nebula Research & Development's 13F filing for Q2 2023, filed 14 Aug 2023.